Physician profile
Evan Sussenbach
NPI 1588954325
$4,646.29
in general payments reported to CMS, 2019-2025
21 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $242 · 2021: $137 · 2022: $426 · 2023: $778 · 2024: $1,249 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,589.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $700.29 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $632.45 | 2024-2025 | Xdemvy |
| Abbvie INC. | $610.72 | 2022-2025 | Durysta, Lumigan, Vuity |
| Alcon Vision LLC | $437.94 | 2019-2025 | Clareon, Lensx, Tryptyr |
| Bausch & Lomb Americas INC. | $425.18 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Glaukos Corporation | $373.61 | 2025 | Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $272.62 | 2019-2021 | |
| Allergan, INC. | $229.77 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $171.15 | 2022-2025 | Purified Cortrophin Gel |
| Amgen INC. | $144.31 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $124.75 | 2022 | |
| Tearlab Corp | $118.15 | 2023 | Tearlab Osmolarity System |
| Harrow Eye, LLC | $106.40 | 2025 | Vevye |
| Rxsight INC | $72.82 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $59.79 | 2024-2025 | Tyrvaya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $56.76 | 2019-2021 | |
| Shire North American Group INC | $32.00 | 2019 | |
| Alimera Sciences, INC. | $21.74 | 2024 | Iluvien, Yutiq |
| Biotissue Holdings INC. | $20.00 | 2025 | |
| Thea Pharma INC. | $19.52 | 2024 | Iyuzeh |
| Ocular Therapeutix, INC. | $16.32 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Sussenbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.